Skip to main content

Day: June 8, 2022

iSpecimen Appoints Evan Cox as Vice President of Product Management

Industry Veteran Brings Nearly Two Decades of Experience in Healthcare Product Management to the Company LEXINGTON, Mass., June 08, 2022 (GLOBE NEWSWIRE) — iSpecimen Inc. (Nasdaq: ISPC) (“iSpecimen” or the “Company”), an online global marketplace that connects scientists in need of biospecimens for medical research with a network of healthcare specimen providers, announced today that the Company has appointed Evan Cox as Vice President of Product Management, effective immediately. In this role, Mr. Cox will manage the growth and future development of the iSpecimen Marketplace™ platform. “Evan’s previous experience in planning, developing and delivering technology solutions for leading healthcare organizations will prove vital as we continue to enhance and expand our Marketplace offering,” said iSpecimen Founder and CEO, Christopher...

Continue reading

Crinetics Presents Clinical and Research Results at ENDO 2022

CRN04894 Selected for Oral Presentation SAN DIEGO, June 08, 2022 (GLOBE NEWSWIRE) — Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) announced that results from the company’s Phase 1 study of CRN04894, the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia (CAH) and other conditions driven by excess adrenocorticotropic hormone (ACTH), were selected for an oral presentation at ENDO 2022, the Endocrine Society’s annual meeting. Crinetics recently reported that administration of CRN04894 reduced both serum cortisol levels and 24-hour urine free cortisol excretion in the presence of sustained, disease-like ACTH concentrations in multiple-ascending dose cohorts of a Phase 1 study. Results from the company’s Phase 1 study of CRN04777, the company’s investigational candidate for the...

Continue reading

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

PURCHASE, N.Y., June 08, 2022 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lisa Ricciardi, Cognition’s president and CEO will be presenting an update on the company’s progress developing small-molecule therapeutics targeting age-related degenerative diseases of the central nervous system and retina. A live and archived webcast can be accessed here as well as on the company’s Events & Presentations webpage.Presentation details:Location: Lotte New York Palace Hotel, Holmes IIDate: Thursday, June 16Time: 12:30 PMAbout Cognition TherapeuticsCognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of innovative, small molecule therapeutics...

Continue reading

Ollie’s Bargain Outlet Holdings, Inc. Reports First Quarter Fiscal 2022 Financial Results

Announces Departure of Chief Financial Officer HARRISBURG, Pa., June 08, 2022 (GLOBE NEWSWIRE) — Ollie’s Bargain Outlet Holdings, Inc. (NASDAQ: OLLI) (the “Company”) today reported financial results for the first quarter ended April 30, 2022. First Quarter Summary:Total net sales decreased 10.1% to $406.7 million. Comparable store sales decreased 17.3% from the prior year increase of 18.8%. The Company opened 9 new stores and closed one store in connection with a relocation, ending the quarter with 439 stores in 29 states, a year-over-year increase in store count of 10.6%. Operating income decreased 75.9% to $17.1 million and operating margin decreased 1,150 basis points to 4.2%. Net income decreased 77.3% to $12.5 million and net income per diluted share decreased 76.2% to $0.20. Adjusted net income(1) decreased 76.0% to $12.8...

Continue reading

Daktronics, Inc. Announces Fiscal Year and Fourth Quarter 2022 Results

BROOKINGS, S.D., June 08, 2022 (GLOBE NEWSWIRE) — Daktronics, Inc. (NASDAQ – DAKT) today reported fiscal year and fourth quarter 2022 results. Fiscal 2022 financial highlights:Fiscal net sales of $611.0 million as a result of record orders and eased pandemic related site restrictions Operating income of $4.0 million realized through headwinds of inflation in materials, personnel and freight related expenses Product order backlog of $472 million(1), driven by record order volume of $846.1 million(1) and softer conversion to sales due to supply chain challengesReflection on FY2022 Reece Kurtenbach, chairman, president and chief executive officer, stated, “Thank you to our Daktronics team for increasing our capacity, adjusting to the uncertain and volatile supply chain conditions, and serving our customers as our industry...

Continue reading

Trailbreaker Resources Completes Phase 1 Geophysical and Geochemical Surveys at Its Eakin Creek Property in South-Central BC

VANCOUVER, British Columbia, June 08, 2022 (GLOBE NEWSWIRE) — Trailbreaker Resources Ltd. (TBK.V) (“Trailbreaker” or “the Company”) is pleased to announce the completion of its Phase 1 exploration program at their Eakin Creek property in south-central British Columbia (BC). The program was designed to evaluate the known gold showings and to help in de-risking potential future drill programs. Phase 1 consisted of an induced polarization (IP) and resistivity survey, a mobile metal ion (MMI) soil geochemical survey, prospecting and geological reconnaissance. Details of the Phase 1 program (Results pending)11 line-kilometers of deep-penetrating IP and resistivity surveying 90 prospecting grab samples 301 soil samples undergoing MMI analysis, covering a 1.8 x 1.4-kilometre areaAbout Eakin Creek The Eakin Creek property lies in an...

Continue reading

Drilling Underway for 24,000 Meter Program at Goliath’s Extensive New High-Grade Gold-Silver Discovery in the Golden Triangle, B.C.

Infographic 1 Infographic 1Infographic 2 Infographic 2Newly Discovered Surebet Zone & New Extension Target Highlights:Fully funded 24,000 meter drilling campaign is underway totaling 85 holes from 24 separate drill pad locations with four diamond drill rigs.The 2022 campaign will include resource level infill drilling as well as targeting the outer extremities of the known gold- silver zone down-dip to trace the extent of this extensive high grade system that remains open.An accompanying infographic is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/cae6ef0e-5738-4184-bf75-7d45fd0847dc 100% of all 24 holes drilled during the 2021 maiden campaign totalling 5,332 meters intersected significant widths of high-grade gold-silver mineralization over 1 km of strike and confirmed 1.1 km of down dip extent:GD-21-03...

Continue reading

Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022

SAN FRANCISCO, June 08, 2022 (GLOBE NEWSWIRE) — Vir Biotechnology, Inc. (Nasdaq: VIR) today announced that three abstracts highlighting data from its hepatitis B virus (HBV) program have been accepted for one oral and two poster presentations at the International Liver Congress™ 2022 (ILC), the Annual Meeting of the European Association for the Study of the Liver (EASL), taking place in London and online June 22-26. The oral presentation will highlight new dose and duration data from a Phase 2 trial evaluating VIR-2218, an investigational HBV-targeting small interfering ribonucleic acid (siRNA) that mediates RNA interference, for the potential functional cure of chronic HBV infection. One poster presentation will highlight dose-dependent durability data from a Phase 1 trial of VIR-3434, an investigational HBV-neutralizing monoclonal...

Continue reading

Where visual content meets data: New iStock VisualGPS Insights tool empowers businesses to take a data-driven approach to marketing

A Media Snippet accompanying this announcement is available by clicking on the image or link below:NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) — iStock, a leading e-commerce platform providing premium content to SMBs, SMEs, creatives, and students everywhere, has launched VisualGPS Insights, an interactive tool that helps businesses make smarter decisions about their visual content. An industry first, this dynamic dashboard uses real-time iStock.com search and download data to surface global insights, easing the process of selecting imagery that resonates with consumers. To provide customers visual guidance, VisualGPS Insights helps small businesses and freelancer creatives to choose relevant and inspiring visual concepts that are meaningful to consumers and drive real results. Early adopters, including business owners, are seeing...

Continue reading

Immunovant Achieves Alignment with FDA on Plans for Phase 3 Clinical Trials of Batoclimab in Thyroid Eye Disease and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2022

Immunovant plans to initiate two placebo-controlled Phase 3 clinical trials of batoclimab in thyroid eye disease (TED) in the second half of calendar year 2022 with top-line data expected for both in the first half of calendar year 2025 Immunovant estimates annual addressable U.S. TED population for a new mechanism of action to be 8,000-18,000 patients Immunovant on track to initiate pivotal Phase 3 clinical trial of batoclimab in myasthenia gravis (MG), by the end of June 2022 Cash balance of $494 million as of March 31, 2022 expected to provide cash runway into calendar year 2025NEW YORK, June 08, 2022 (GLOBE NEWSWIRE) — Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today announced that it has achieved alignment with the United...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.